Immunotherapies in Hepatocellular Carcinomas
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".
Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 2666
Special Issue Editor
Special Issue Information
Dear Colleagues,
Hepatocellular carcinoma (HCC) is one of the most insidious malignant tumors and it remains one of the leading causes of death from all types of cancers. Usually, it shows late clinical signs in the advanced stages of the disease, which results in a frequent delay in diagnosis. The prognosis for HCC remains poor despite multidisciplinary medical approach and many therapeutical advances. Still, surgical resection and liver transplantation remain the main ways of radical treatment for HCC. In recent years, locoregional interventional therapies and targeted immunotherapies also have become increasingly important, especially for patients in advanced stages of the disease. However, we still do not have modern systemic drugs available, that would allow us to prolong life of our HCC patients for many years.
This Special Issue is designed to summarize all the recent knowledge on immunotherapeutic treatment options for HCC, with special interest on the advances in indications, drugs and their clinical implications and also, some recent research directions in that matter. We encourage authors to publish articles both in the field of clinical and laboratory science to achieve the best cross-sectional scientific effect of this Special Issue.
Dr. Michał P. Wasilewicz
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hepatocellular carcinoma
- HCC
- liver tumors
- liver cancer
- systemic therapies
- immunochemotherapy
- immunotherapy
- adjuvant therapy
- neoadjuvant therapy
- targeted therapies
- hepatocellular carcinoma microenvironment
